| March
16, 2007
Zinc supplements may cut deaths among low-income
kids
By Stephen Daniells
16/03/2007 - Daily zinc supplements reduced the risk
of death among children aged 12 to 48 months by 18 per cent, says
a clinical trial set in Zanzibar.
The study, published in the new issue of The Lancet, adds further
evidence to the immune boosting properties of the element, with
other trials also showing reduced frequency of pneumonia and diarrhoea
in low-income settings.
"This large trial demonstrates that the benefits of zinc
supplementation include mortality reduction in addition to the
reduction in cases of pneumonia, diarrhoea and malaria that we
found in previous trials," said senior author Robert Black
from at the Johns Hopkins Bloomberg School of Public Health.
Zinc is one of the most plentiful trace elements in the body,
second only to iron. It mediates many physiological functions
and is believed to be essential for maintaining a healthy immune
system.
The double-blind, placebo-controlled trial involved 42,546 children
(age range 1 to 36 months) living in Pemba, Zanzibar and randomly
assigned to receive with daily zinc supplements (10 mg per day,
5 mg in children under 12 months), or placebo for an average of
485 days.
Lead author Sunil Sazawal reports that, while no statistically
significant reduction in mortality was observed for the overall
population group (seven per cent reduction), amongst the children
aged between 12 to 48 months, a statistically significant 18 per
cent reduction in mortality was observed.
Possible explanations for this observations, said the researchers,
could include infants getting sufficient amounts of zinc in utero
and through breast-feeding to sustain them during the first year
of life, or may also be a result of the lower doses of zinc given
to infants (5 mg) compared to the higher doses given to older
children (10 mg).
"Our findings of no effect in infants needs further investigation
with existing datasets, and in subsequent studies because they
could have important implications for targeting children who would
benefit from additional zinc," wrote the authors.
"While further work is needed to evaluate higher dose effects,
recommendations for use of zinc as a preventive strategy needs
to consider the collective evidence of the effect on growth, morbidity
and mortality, which would suggest benefit in children age 6 months
and up," said Sazawal.
In an accompanying editorial by Shinjini Bhatnagar from the All
India Institute of Medical Sciences in New Delhi said that Sazawal's
study raised some important policy issues.
"Could the varying doses of zinc used for these mortality
studies have affected the results?" asked Bhatnagar.
"One is tempted to speculate that larger doses than those
used in the trial in Zanzibar could be more beneficial in the
reduction of mortality than was actually seen. An obvious lesson
is that increased emphasis should be given to studying specific
mechanisms by which zinc acts, and whether the benefits are related
to correction of zinc deficiency or to favourable effects of zinc
at increasing concentrations. Such knowledge could guide definition
of a rationale for a daily optimum dose," said Bhatnagar.
"In the interim, the present WHO strategy to focus on introduction
of zinc for treatment of diarrhoea is an important step forward,"
concluded the editorial. "In the long-term, measures to improve
zinc intake of children, such as improvement of the overall diet,
supplementation, food fortification, and sub-selection of crops
with improved zinc content need to be explored and assessed."
Source: The Lancet
17 March 2007, Volume 369, Pages 927-934; doi:10.1016/S0140-6736(07)60452-8
"Effect of zinc supplementation on mortality in children
aged 1-48 months: a community-based randomised placebo-controlled
trial"
Authors: S. Sazawal, R.E. Black, M. Ramsan, H.M. Chwaya, A. Dutta,
R.J. Stoltzfus, M.K. Othman, F.M. Kabole
Editorial: The Lancet
17 March 2007, Volume 369, Pages 885-886
"Effects of zinc supplementation on child mortality"
Author: S. Bhatnagar
Source: www.nutraingredients.com
Comment:
This study further adds to the evidence verifying the importance
of cellular nutrients for health. This study, published
in The Lancet and conducted in a large population, demonstrates
the benefits of zinc supplementation - including mortality
reduction in addition to the reduction in cases of pneumonia,
diarrhea and malaria. Zinc mediates many physiological functions
and is believed to be essential for maintaining a healthy
immune system. This once again confirms what Dr. Rath has
shown in his research and clinical findings, that cellular
nutrients are helpful in fighting many chronic diseases
including infectious diseases. In contrast to this research
with a single nutrient, Dr. Rath’s research shows
that it is not just one nutrient but rather the synergistic
combination of specific nutrients (vitamins, minerals and
amino acids) that provide the maximum benefit. To read more
about Dr. Rath’s research in various conditions please
visit http://www.drrathresearch.org/ |
|